PharmaShots

PharmaShots Weekly Snapshot (September 16– 20, 2019)

September 23, 2019October 11, 2019Tuba Khan

1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, [Read More...]

Acceleron to Discontinue P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy

Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy

September 17, 2019September 17, 2019Tuba Khan

Shots: The P-II clinical study involves assessing ACE-083 in FSHD patient with muscle weakness in the biceps brachii, the tibialis anterior, and a [Read More...]

Celgene and Acceleron Report FDA’s Acceptance of BLA for Luspatercept to Treat Myelodysplastic Syndromes and Beta-Thalassemia

June 4, 2019June 12, 2019Shiwani Sharma

Shots: The BLA acceptance follows safety and efficacy data from two P-III MEDALIST and BELIEVE study result assessing Luspatercept vs PBO to treat [Read More...]

Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to the US FDA for Luspatercept

April 8, 2019June 13, 2019Tuba Khan

Shots: The BLA submission is based on P-III MEDALIST & BELIEVE studies. The P-III MEDALIST study involves assessing of luspatercept (1.0 mg/kg) vs [Read More...]

Acceleron’s ACE-083 Receives FDA’s ODD for Charcot Marie Tooth Disease (CMT)

March 6, 2019June 14, 2019Shiwani Sharma

Shots: The ODD designation follows two P-II studies assessing ACE-083 (Myostatin+ muscle agent) in patients with CMT and facioscapulohumeral muscular dystrophy (FSHD) The [Read More...]